HIGHLIGHTS
- who: Jiajia Ma from the University of California, Los Angeles, United States have published the article: The immune checkpoint expression in the tumor immune microenvironment of DLBCL: Clinicopathologic features and prognosis, in the Journal: (JOURNAL)
- how: The clinical relevance of PD-1 LAG-3 TIM-3 TIGIT and other clinicopathologic data were evaluated using the Chi-square test and rank sum test.
- future: The authors haven`t found the clue that TIGIT can be used as a new immunotherapy target yet and further research is needed to explore its biological significance.
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.